Microsoft word - rheumors spring 1992.doc

Volume 3, Number 2
Spring 1992



by Robert L. Rosenberg, M.D.
We all tend to think of arthritis and rheumatic diseases as affecting only our joints. While this is
mostly true for osteoarthritis, many other types of arthritis pose the risk of multiple organ system
(systemic) involvement.
Systemic involvement can manifest as medical problems occurring in one or more of the organ
systems. The skin, muscles, kidney, lungs, heart, stomach, nerves and other body parts can
become diseased causing organ malfunction and illness. Indeed, the fevers and fatigue often seen
in arthritis are due to the systemic nature of the diseases. It is not unusual to feel like you have
"the flu" when your arthritis is active.
Rheumatoid arthritis may cause skin nodules, eye inflammation, salivary gland malfunction
(resulting in mouth dryness), nerve entrapment with numbness and severe fatigue. Fortunately,
involvement of the heart, lungs, kidneys and blood forming elements in the bone marrow are less
frequent, but potentially severe nonetheless. Commonly, rheumatoid arthritis and other
inflammatory diseases such as systemic lupus erythematosus (SLE) and ankylosing spondylitis
can cause osteoporosis with subsequent thinning of bone and increased risk of bone fracture.
SLE can also cause severe kidney damage, blood vessel changes and central nervous system
disturbances. When these occur, they must be treated aggressively.
Ankylosing spondylitis is sometimes associated with heart, blood, and lung problems. Any
chronic inflammatory disease may lead to the later development of Amyloidosis - a rare
accumulation of abnormal proteins in internal organs that may cause these organs to malfunction
and fail. Patients with longstanding arthritis should be observed for these potential
complications. Last, but certainly not least, there are potential systemic risks for many of the
medicines we use to treat severe arthritis. The anti-inflammatory drugs, steroids, Methotrexate,
Plaquenil, Imuran, pain relievers, Gold, Depenicillamine and Cytoxan all are capable of systemic
side effects. Modification of drug dose and even stopping a drug may be necessary on occasion.
You may think we rheumatologists are just looking at your joints - actually we are looking at all
of you, listening for hints and searching for signs that you may be experiencing some of these
systemic problems. Only by carefully anticipating problems can we treat them early, hopefully
preventing later complications.
Although arthritis means "inflammation of joints" - it may signal that other parts of the body are
likewise involved. Extra-articular involvement, "outside the joints", can lead to major illness and
disability. Thorough examination and treatment will help keep systemic involvement to a minimum. WHAT KIND OF DOCTOR WOULD YOU SEE FOR . . . . .

In today's world of medical specialization patients often do not know what kind of doctor to see
for specific problems. A short QUIZ follows. For each of the following medical problems,
decide which specialist you would consider consulting.
Who would you consult if you were concerned about . . .
Back Pain?
Carpal tunnel syndrome?
The answer to all the above is your rheumatologist! At ARA we have extensive experience
treating all the above conditions, as well as a variety of other musculoskeletal disorders. Often
we can help patients avoid surgery for problems such as carpal tunnel syndrome. Our special
interests lie in the treatment of arthritic conditions and osteoporosis, and we now offer even
greater patient access to therapies on the leading edge of technology.
Arthritis & Rheumatism is the definitive journal of Rheumatology in our country and the world.
Rheumatologists recognize it as the leading information source for current research and treatment
for their specialty.
Our own Dr. Evan L. Siegel is co-author of the lead article in the May issue of Arthritis &
Rheumatism. His research involved looking at the effects of the nervous system on inflammation. Arthritis & Rheumatism Associates is proud of Dr. Siegel's contribution to rheumatology research.


What is Paget's disease of the bone?
Paget's disease of the bone is a disorder of increased bone reabsorption and subsequent excess bone formation. The cause of this disorder is unknown. The disease may involve only one bone (monostotic) or multiple bones (polyostotic). Most patient's with Paget's disease are without symptoms, and the disease is usually recognized incidentally when xrays for other disorders reveal findings compatible with Paget's. The doctors at Arthritis & Rheumatism Associates have vast experience with the diagnosis and treatment of this metabolic bone disease. What is osteomyelitis?
Osteomyelitis is a bacterial infection of the bone. Many type of bacteria can cause osteomyelitis which may result from direct blood borne infection or spread from adjacent tissue. Osteomyelitis may also be associated with poor circulation (peripheral vascular disease). Treatment includes appropriate antibiotic therapy and, if necessary, surgical intervention. What will a copper bracelet do for my arthritis?
Probably very little. The use of copper in healing dates back to the ancient Egyptians and Greeks. Even modern folklore holds the copper bracelet as having certain curative properties for arthritis. Although some poorly controlled and inadequately designed studies have shown limited effectiveness, there is little scientific evidence to allow confidence in the use of a copper bracelet as the sole treatment for arthritis. If you'd like to chance a "cure" it wouldn't hurt you, but it probably wouldn't help you either. Use it along with your aspirin! Herbert S.B. Baraf, M.D.
Arthritis & Rheumatism Associates have developed the Osteoporosis Treatment Section. We
have vast experience in diagnosis of the disorder of osteoporosis using the latest techniques both
by bone mineral densitometry using DPX (dual photon xray), advanced chemical studies, and
general xrays. Vast experience has been gained in using those therapies that have been cleared
by the Food & Drug Administration for treatment and we are presently gearing up for a number
of studies using experimental medications for the treatment of osteoporosis.
By Evan L. Siegel, M.D.
The clues for this crossword puzzle have been drawn from past and present RHEUMORS
articles. Test your memory by filling in the squares, then check your answers on page.

Herbert S. B. Baraf, M.D.
Experienced readers of Rheumors have learned that there are more than one hundred different
types of arthritic conditions. The two principle forms of arthritis, Osteoarthritis (OA) and
Rheumatoid Arthritis (RA), have similarities in the way they are treated. However, there are
some treatments that are quite specific for certain forms of arthritis.
The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have been the mainstay of the medical
therapy of arthritis and both OA and RA patients are treated with these agents. The first NSAID
was aspirin, originally marketed by Bayer Pharmaceuticals in the late 1890's. The second
available NSAID was released for use in the early 1950's. By the mid-1970's the number of
available NSAIDs proliferated as Naprosyn, Clinoril, Nalfon, Tolectin and others were
released. The last ten years has seen at least ten more new NSAIDs come to market.
This wide variety of NSAIDs has given the Rheumatologist an opportunity to tailor treatment to
the specific requirements of his or her patients - differences in dosing, interaction with other
medications or toxicities, etc., and is one of the great advances in treatment of recent years. It
has been found that there is no one superior drug for a given condition. The individual patient
may unpredictably vary in his or her response to these agents. Thus, each time a new drug is
introduced, patients who have failed to respond to old medications have reason to be hopeful.
In the past few years, four important new NSAIDs were released; Lodine (etodolac), Voltaren
(diclofenac), Ansaid (flurbiprofen) and Relafen (nambutone). We are proud that we
participated in the clinical trials that were essential in getting three of these agents approved. As
physicians actively involved in clinical research, we have a unique perspective on present and
future therapies. Those patients that have assisted in this process also have reason for a sense of
accomplishment in their role of advancing treatment of the rheumatic diseases.
Unfortunately, in RA, NSAID therapy alone is usually not enough to keep joint pain and swelling
under control. Patients who fail to respond adequately to a series of trials with NSAIDs must
often be treated with second-line therapies collectively referred to as DMARDs (Disease
Modifying Anti-Rheumatic Drugs). The traditional DMARDs include injectable gold therapy
and anti-malarial agents. Gold remains today as one of our most effective therapies for active
Hydroxychloroquine (Plaquenil) is a drug originally developed for use in treating malaria. In
the 1950's a series of reports indicated that related anti-malarial compounds were useful in both
RA and Lupus (SLE). Anti-malarial drugs have proven to be among the safest and best tolerated
DMARDs presently in use.
Perhaps the most significant advance in recent years has been the introduction and general
acceptance of Methotrexate as a treatment for RA. In the first several years after its introduction
in 1948 it remained primarily a "cancer drug" used to treat a variety of solid tumors and bone
marrow malignancy. In the 1960's its use in psoriasis, a troublesome skin condition, became
widespread. By the late 1970's its use in RA was reinvestigated. Rheumatologists around the
world have been using this drug with increasing frequency for the past ten years with remarkable
results and an excellent safety record.
Other anti-cancer drugs have been used in RA, notably azathioprine (Imuran) and
cyclophosphamide (Cytoxan). These drugs are presently reserved for patients who have not
responded to the above treatments.
A number of experimental arthritis treatments continue to be investigated. Our practice was
engaged in clinical trials of Azulfidine, an agent in widespread use for inflammmatory
conditions of the intestines, and Therafectin, a drug of low toxicity that may eventually prove to
be useful.
Immunology advances have led to new agents that interfere with the immune response potentially
offering benefits in RA & SLE. Experimental manipulations of lymphocytes, the cell central in
causing and perpetuating inflammation, will likely yield new treatments for the Rheumatic
We have come a long way to ease pain and suffering and to control Rheumatic Diseases. We
have even greater hope for the years ahead. Continued research is the key to finding new
treatments, and possibly cures, for the various forms of arthritis.
A quarterly publication brought to you by Arthritis & Rheumatism Associates, P.C. Norman S. Koval, M.D. Herbert S. B. Baraf, M.D. Robert L. Rosenberg, M.D. Evan L. Siegel, M.D. Emma DiIorio, M.D. Margaret Dieckhoner, Editor  1990 Arthritis & Rheumatism Associates


Pqje118805 1224.1236

THE QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY2006, 59 (7), 1224 – 1236Heinrich-Heine-Universita¨t, Du¨sseldorf, GermanyPerformance of 28 schizophrenic patients and 28 matched controls was compared in an auditorypriming task. A large auditory negative priming effect was obtained for the patients as well as forthe control group, and the size of the negative priming effect was approximatel

Pii: s0928-4257(00)00154-6

J. Physiol. (Paris) 94 (2000) 135−138© 2000 Elsevier Science Ltd. Published by Éditions scientifiques et médicales Elsevier SAS. All rights reservedS0928425700001546/FLA Modulation by GABA and delta opioid receptors of neurally induced responses in isolated guinea-pig taenia coli and human colonic circular muscle Éva Makóa,b*, András Z Rónaia, György Ádámb, Gábor Juhászb,L

Copyright © 2010-2014 Metabolize Drugs Pdf